PRESS RELEASE
News
-
-
-
PRESS RELEASE
JDC Group AG: Record final quarter brings JDC Group 2023 30 percent EBITDA increase with double-digit revenue growth
JDC Group AG reported a record final quarter in 2023 with a 30% increase in EBITDA and double-digit revenue growth, expecting strong growth for 2024. Preliminary figures show promising results -
-
-
PRESS RELEASE
Approval of temporary exemptions from conditions for maintaining the listing in accordance with article 7 Listing Rules and the delisting of Crealogix Holding AG's registered shares
SIX Exchange Regulation AG grants temporary exemptions from listing conditions and approves delisting of Crealogix Holding AG's registered shares following approval request by the company -
PRESS RELEASE
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Kuros Biosciences to report full-year financial results for 2023 and provide corporate update on March 13, 2024, with a conference call and webcast scheduled. Company overview and contact information included -
PRESS RELEASE
R&S Group acknowledges VERAISON’s decision to gradually return capital to its shareholders
R&S Group Holding AG acknowledges VERAISON's decision to gradually return capital to its shareholders. VERAISON, sponsor of SPAC VT5 Acquisition Company AG, still holds approximately 6% of RSGN shares -
REGULATED PRESS RELEASE
Biophytis a présenté le potentiel de RuvembriTM dans le traitement de la dystrophie musculaire de Duchenne
Biophytis présente les résultats prometteurs de RuvembriTM dans le traitement de la dystrophie musculaire de Duchenne lors de la MDA Clinical & Scientific Conference. Objectif : essai clinique de phase 1-2 en 2024 -
REGULATED PRESS RELEASE
Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy
Biophytis presents RuvembriTM potential in Duchenne Muscular Dystrophy treatment at MDA Conference, showing efficacy in clinical trials. CEO highlights medical need and market value increase
